Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Impact of fixed-dose combination drugs on adherence to prescription medications.

Pan F, Chernew ME, Fendrick AM.

J Gen Intern Med. 2008 May;23(5):611-4. doi: 10.1007/s11606-008-0544-x. Epub 2008 Feb 21.

2.
3.
4.
5.

A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.

Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J.

J Med Econ. 2016;19(3):203-12. doi: 10.3111/13696998.2015.1109518. Epub 2015 Nov 30.

PMID:
26473990
7.

Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.

Kim S, Jang IJ, Shin D, Shin DS, Yoon S, Lim KS, Yu KS, Li J, Zhang H, Liu Y, Brendel E, Blode H, Wang Y.

J Clin Pharm Ther. 2014 Aug;39(4):424-31. doi: 10.1111/jcpt.12166. Epub 2014 May 8.

PMID:
24806030
8.

Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.

Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.

JAMA Intern Med. 2014 Dec;174(12):1955-62. doi: 10.1001/jamainternmed.2014.5294.

PMID:
25347323
9.

Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.

Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S.

Adv Ther. 2012 Jan;29(1):26-40. doi: 10.1007/s12325-011-0096-z. Epub 2012 Jan 12.

PMID:
22246944
10.
11.

Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.

Duckworth W, Marcelli M, Padden M, Kellick K, Duhancik T, Wilhardt M, Colgan K, Romie A.

J Manag Care Pharm. 2003 May-Jun;9(3):256-62.

12.

Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.

Roselli A, Hayes JD, Seidner R, Marchione V, Snyder CM, Mayes K, Stiernberg CM, Milgram L.

Manag Care. 2001 Feb;10(2 Suppl):17-21. No abstract available.

14.

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.

Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS.

Drug Des Devel Ther. 2015 Feb 4;9:729-36. doi: 10.2147/DDDT.S75980. eCollection 2015.

15.

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.

Perez A, Zhao Z, Jacks R, Spanheimer R.

Curr Med Res Opin. 2009 Dec;25(12):2915-23. doi: 10.1185/03007990903350011.

PMID:
19827910
16.

Glyburide/metformin (Glucovance) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2000 Nov 13;42(1092):105-6. No abstract available.

PMID:
11077467
17.

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP.

Clin Drug Investig. 2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000.

PMID:
21819160
18.

Electronic monitoring and counseling to improve medication adherence.

Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA.

Behav Res Ther. 2004 Apr;42(4):409-22.

PMID:
14998735
19.

Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.

Upreti VV, Keung CF, Boulton DW, Chang M, Li L, Tang A, Hsiang BC, Quamina-Edghill D, Frevert EU, Lacreta FP.

Clin Drug Investig. 2013 May;33(5):365-74. doi: 10.1007/s40261-013-0075-z.

PMID:
23549864
20.

Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations.

Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A.

Curr Med Res Opin. 2008 Sep;24(9):2597-607. doi: 10.1185/03007990802319364 .

PMID:
18812017

Supplemental Content

Support Center